Study advances case for targeted BRD metaphylaxis in cattle: full analysis
A familiar reality in feedlot medicine is getting a harder scientific look: some cattle given arrival metaphylaxis for bovine respiratory disease may never have needed it. Newer work from a Texas A&M-led collaboration is helping explain why. In a Frontiers in Immunology study published September 13, 2024, investigators reported that high-risk beef cattle showed distinct whole-blood gene-expression patterns associated with later BRD development and severity, adding to a multi-year effort to identify biomarkers that could move the industry from broad risk-based metaphylaxis toward more targeted antimicrobial decisions. (frontiersin.org)
The backdrop is well known to bovine practitioners. BRD remains the leading infectious disease challenge in beef production, and Texas A&M notes it costs the cattle industry about $1 billion annually in prevention, treatment, management, and losses. Because veterinarians still can’t reliably predict which individual high-risk arrivals will become clinical cases, metaphylaxis has remained a common preventive strategy at feedlot arrival, especially for auction-sourced, recently weaned, commingled cattle. (vetmed.tamu.edu)
What’s changed is the strength and continuity of the biomarker story. The group’s earlier PLOS One paper, published in 2020, described itself as the first report of whole-blood transcriptomes in high-risk beef cattle at arrival aimed at identifying RNA biomarkers and molecular pathways associated with later BRD or natural resistance. In that study, 24 randomly sampled high-risk cattle were followed after arrival, 11 were treated for BRD within 28 days, and sequencing on a subset of healthy and BRD animals identified differentially expressed genes present before clinical disease was recognized. The 2024 Frontiers paper extends that approach with a time-course design, showing that BRD-associated transcriptional differences are not limited to a single sampling point and may reflect persistent inflammatory and airway-related changes weeks after treatment. (pmc.ncbi.nlm.nih.gov)
The work also appears to be part of a larger, still-evolving research program rather than a one-off finding. The 2024 paper cites two intermediary studies from the same research line: a 2021 Scientific Reports validation study and a 2022 BMC Veterinary Research paper using nCounter mRNA profiling to identify at-arrival gene-expression patterns predictive of BRD. Separately, Texas A&M announced in October 2023 that a USDA NIFA grant would support a collaborative project with Mississippi State University, West Texas A&M University, and Texas A&M AgriLife to track cattle across the production cycle, analyze host gene expression, and study upper respiratory microbial communities tied to BRD risk. Conference abstracts presented in 2025 suggest the collaboration has already expanded into multiomic work that combines blood RNA sequencing with nasal metagenomics and management variables such as vaccination and marketing stress. (frontiersin.org)
That broader context matters because BRD risk prediction is increasingly being framed as a stewardship tool, not just a diagnostic ambition. USDA project materials tied to the Texas A&M program explicitly state that discovering biomarkers that better predict cattle at high risk for BRD could advance adoption of targeted metaphylaxis, reduce antimicrobial use, and improve welfare. Meanwhile, other recent BRD studies are showing that information gathered near arrival or around two weeks on feed can help predict later treatment risk and antimicrobial susceptibility patterns. In a 2024 Frontiers in Veterinary Science paper, calves sampled at 13 days on feed yielded better-fitting models for later BRD treatment and susceptibility outcomes than sampling at arrival, underscoring that precision antimicrobial use in feedlots may ultimately depend on combining host, pathogen, and timing signals. (portal.nifa.usda.gov)
There doesn’t appear to be much formal outside commentary yet on this specific transcriptomic paper, but the direction of travel aligns with broader industry thinking. The American Association of Bovine Practitioners’ judicious-use guidance emphasizes antimicrobial stewardship and preventive health programs, while still recognizing the need for appropriate therapeutic and control use in cattle. That’s the tension this research is trying to resolve: metaphylaxis works in the right populations, but better tools could help veterinarians apply it more selectively rather than relying mainly on broad arrival-risk categories. (aabp.org)
Why it matters: For veterinary professionals, the significance isn’t that metaphylaxis is suddenly obsolete. It’s that the evidence base for a more discriminating alternative is getting stronger. If validated in larger commercial cohorts and translated into a practical assay, arrival-time or early-post-arrival biomarker panels could support more defensible antimicrobial protocols, better case selection, and stronger conversations with feedlot clients about stewardship, efficacy, and cost. They could also help bridge a gap that practitioners know well: current BRD prevention decisions are often made at the cohort level, while disease risk and treatment benefit actually vary animal to animal. (frontiersin.org)
What to watch: The next questions are practical ones: whether these signatures hold up across geographies, cattle types, and management systems, whether they outperform simpler clinical or microbiologic predictors, and whether they can be packaged into an affordable decision-support tool. The science is moving beyond “can we find a signal?” toward “can veterinarians use it in time to change treatment decisions?” That timeline will likely depend on prospective field validation, assay development, and integration with parallel work on microbial profiling and antimicrobial susceptibility. (frontiersin.org)